Viyash Scientific Reports Strong Q2 FY27 Results with PAT Growth of 16.1% YoY
Sequent Scientific Ltd · Press Release · 14 Nov 2026, 12:04 am
Viyash Scientific Reports Strong Q2 FY27 Results with PAT Growth of 16.1% YoY Viyash Scientific reported Q2 FY27 revenue from operations of ₹9,879 Mn, up 16.2% YoY and 4.4% QoQ. Pre-ESOP EBITDA rose 10.3% YoY to ₹2,077 Mn with a 21.0% margin. PAT grew 16.1% YoY to ₹847 Mn, while Adjusted PAT reached ₹1,110 Mn. For H1 FY27, revenue climbed 17.8% YoY to ₹19,343 Mn and PAT surged 49.4% YoY to ₹1,639 Mn. Balance sheet strength improved with Net Debt/EBITDA declining to 0.0x from 0.7x last year. The company completed its BioForLife acquisition in Italy and is expanding oncology and API capacities.
Original exchange filing (PDF)
More announcements from Sequent Scientific Ltd
- Earnings Call Transcript is attached. · 17 Nov 2026
- Please find attached disclosure regarding outcome of the Earnings Call · 14 Nov 2026
- Investor Presentation is attached. · 14 Nov 2026
- Please find attached. · 13 Nov 2026
- Viyash Scientific Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Please find attached. · 13 Nov 2026
- Allotment of ESOP · 03 Nov 2026
- Intimation of Q2 FY27 Earnings Conference Call / Discussion on Financial Results for Quarter and Half Year Ended September 30, 2026. · 14 Nov 2026
